Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
4.330
-0.020 (-0.46%)
Jun 5, 2025, 4:00 PM - Market closed
Avalo Therapeutics Stock Forecast
AVTX's stock price has decreased by -60.64% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Avalo Therapeutics stock ranges from a low of $15 to a high of $48. The average analyst price target of $31 forecasts a 615.94% increase in the stock price over the next year.
Price Target: $31.00 (+615.94%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Avalo Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 4 | 4 | 4 | 5 |
| Buy | 1 | 2 | 2 | 2 | 2 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +246.42% | Jun 2, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +431.18% | Mar 25, 2025 |
| Stifel | Stifel | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +731.41% | Mar 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 20, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $48 | Buy | Initiates | $48 | +1,008.55% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
n/a
from 441.00K
Revenue Next Year
n/a
EPS This Year
-5.63
from -20.91
EPS Next Year
-4.61
from -5.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.70 | -1.65 | -1.70 | ||
| Avg | -5.63 | -4.61 | -4.04 | ||
| Low | -7.15 | -7.62 | -5.04 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.